

RESEARCH

Open Access

Development and Standardization of a Furosemide Stress Test to Predict the Severity of Acute Kidney Injury

Lakhmir S Chawla^{1,2*}, Danielle L Davison¹, Ermira Brasha-Mitchell¹, Jay L Koyner³, John M Arthur⁴, Andrew D Shaw⁵, James A Tumlin⁶, Sharon A Trevino³, Paul L Kimmel⁷ and Michael G Seneff¹

Abstract

Introduction: In the setting of early acute kidney injury (AKI), **no test** has been shown to definitively **predict** the **progression** to more severe stages.

Methods: We investigated the ability of a furosemide stress test (**FST**) (one-time dose of **1.0 or 1.5 mg/kg** depending on **prior furosemide**-exposure) to **predict** the **development** of **AKIN Stage-III** in 2 cohorts of critically ill subjects with early AKI. Cohort 1 was a **retrospective** cohort who received a FST in the setting of AKI in critically ill patients as part of Southern AKI Network. Cohort 2 was a **prospective** multicenter group of critically ill patients who received their FST in the setting of early AKI.

Results: We studied 77 subjects; 23 from cohort 1 and 54 from cohort 2; 25 (**32.4%**) met the primary endpoint of progression to AKIN-III. Subjects with **progressive AKI** had significantly **lower urine output** following FST in each of the **first 6 hours** ($p < 0.001$). The **area** under the **receiver operator characteristic** curves for the total urine output over the **first 2 hours** following FST to predict progression to AKIN-III was **0.87** ($p = 0.001$). The **ideal-cutoff** for predicting AKI progression during the first 2 hours following FST was a urine volume of less than **200mls(100ml/hr)** with a sensitivity of **87.1%** and specificity **84.1%**.

Conclusions: The FST in subjects with early AKI serves as a novel assessment of tubular function with robust predictive capacity to identify those patients with severe and progressive AKI. Future studies to validate these findings are warranted.

Introduction

Acute kidney injury (AKI) is a clinical syndrome that is associated with significant morbidity and mortality [1,2]. The incidence of **AKI** has more than **doubled** in the past **decade** and is projected to continue to **increase** [3]. Patients with AKI are cared for by a multitude of specialists including, but not limited to: emergency medicine physicians, internists, pediatricians, surgeons, intensivists, and nephrologists [4]. Patients who develop AKI often require renal replacement therapy (RRT), but clinicians often disagree about the optimal timing of the initiation of RRT. During the Acute Kidney Injury Network (AKIN)

multi-disciplinary consensus meeting, the question that was ranked highest was: 'When should RRT be initiated?' [4]. **RRT** is an invasive procedure with **inherent risks**, and one would **not** want to **initiate** this therapy if the patient were **destined** to **recover** renal function **without** intervention. However, a more conservative approach of initiating RRT **late** in the course of the AKI can subject the patient to **adverse** consequences [5]. Thus, **if a test could be devised that predicts the likelihood of progressing to a more severe stage of AKI, decisions regarding optimal timing of RRT initiation would be better informed.**

Because serum **creatinine** and **oliguria** are often **late** signs of significant AKI, more sensitive diagnostic tests are required [6-9]. This clinical need has led to the development of multiple candidate AKI biomarkers [6,8-10]. Because AKI **biomarker** levels change over time depending

* Correspondence: minkchawla@gmail.com

¹Department of Anesthesiology and Critical Care Medicine, George Washington University Medical Center, 900 23rd street, Washington DC, 20037, USA

Full list of author information is available at the end of the article

on the **timing** and **severity** of injury [9], a **functional assessment** of renal function might enhance biomarker performance. Since **most common** form(s) of intrinsic AKI involve **acute tubular injury**, we sought to develop a functional assessment of renal tubular function. Furosemide, a loop diuretic, has pharmacokinetic properties that make it an appealing functional tool. In **contrast to other drugs** cleared by the kidney, **furosemide** is **not effectively filtered** by the **glomerulus**. As an organic **acid**, furosemide is **tightly bound** to serum **proteins** and gains access to the **tubular lumen** by **active secretion** via the human organic anion transporter (hOAT) system in the **proximal** convoluted **tubule** [11,12]. Once in the tubular lumen, furosemide **inhibits luminal active chloride** transport throughout the **thick ascending** limb of Henle, thereby **preventing sodium reabsorption** and resulting in natriuresis and increased urine flow [13-15]. We surmised that furosemide-induced **increases in urine output might be a method to assess the integrity of renal tubular function** in the setting of early AKI. Specifically, we hypothesized that the kidney's response or lack of response to a furosemide challenge, as a **clinical assessment of tubular function**, could **identify** patients with **severe tubular injury before** it was clinically **apparent** (for example, a rise in creatinine). We sought to develop and standardize a furosemide stress test (FST) for patients with AKI and describe its performance characteristics.

Materials and methods

We assembled two separate cohorts of critically ill patients with either **stage I or II AKIN** criteria (Additional file 1 - Table S1) [16], who were given a standardized dose of furosemide, and assessed their response and outcomes.

Cohort 1

The Southern Acute Kidney Injury Network (SAKInet) [17] was formed in 2007 to collect samples from patients who developed AKI, with the goal of testing the diagnostic and prognostic accuracy of previously described and novel AKI biomarkers. For each subject, informed consent was obtained in accordance with The George Washington University Institutional Review Board-approved SAKInet protocol. We identified a subset of patients from the SAKInet cohort at the George Washington University who fulfilled the study criteria.

Cohort 2

The protocol for cohort 2 was registered in clinicaltrials.gov. The study was carried out at the George Washington University (NCT00673244) and at the University of Chicago (NCT01275729). The respective university IRBs approved the identical protocol. Patients or their surrogates were required to sign informed consent prior to study entry. Patients were enrolled from June 2009 through

December 2012. Urine sediment was assessed with the George Washington Urine Sediment Score (GW USS) as described previously [18]. Briefly, patients with a GW USS ≥ 2 have evidence of granular or epithelial cell casts in their urine sediment.

Study criteria (both cohorts 1 and 2)

Inclusion criteria: (1) age greater than 18 years, admitted in an ICU; (2) AKIN stage I (6 hours of oliguria (<0.5 ml/kg/hour) or 0.3 mg/dL increase in serum creatinine or increase of 150 to 200% above baseline serum creatinine), or AKIN stage II (12 hours of oliguria (<0.5 ml/kg/hour) or increase of 200 to 300% above baseline serum creatinine); (3) indwelling bladder catheter; (4) presence of granular or epithelial cell casts on urine sediment (defined by GW USS ≥ 2), or fractional excretion of sodium (FeNa) $>1.0\%$; and (5) patient deemed by the treating clinical team to be well-resuscitated.

Exclusion Criteria: (1) baseline estimated glomerular filtration rate (eGFR) <30 ml/minute/1.73m²; (2) history of renal allograft; (3) known pregnancy; (4) evidence of obstructive uropathy (for example, hydro-ureter); (5) evidence of active bleeding; (6) patients with allergy or known sensitivity to loop diuretics; (7) achievement of AKIN stage III criteria; or (8) evidence of volume depletion at the time of furosemide administration.

Study procedures (cohort 1)

Patients in the SAKInet cohort who met the study criteria, and who received a furosemide dose of 1.0 mg/kg were entered into cohort 1. Replacement fluid was not protocolized in this group of subjects. Demographic and clinical data, urine sediment scores, and outcome data were abstracted from the case report forms.

Study procedures (cohort 2)

Prior to FST urine was collected and scored with the GW USS [18]. Urinalysis was performed at each site (EBM-GW, JLK-UC). A pre-FST FeNa was only available if the treating team had ordered it for clinical purposes. After acquisition of informed consent, patients who were loop-diuretic naïve were given 1.0 mg/kg of intravenous furosemide. Because patients who were previously treated with loop diuretics within the previous 7 days were likely to have a blunted response over time compared to naïve patients, this group received an intravenous dose of 1.5 mg/kg (as little as 6 to 8 days of chronic loop-diuretic therapy is associated with a blunted response to furosemide due to increased distal tubular uptake of sodium in the thiazide-sensitive nephron segment)[19]. In order to minimize the risk of hypovolemia, urine output was replaced ml for ml each hour with either Ringers lactate or normal saline for six hours after the FST. The treating team could elect not to replace the volume if net volume loss was

considered clinically desirable. Urine output was measured hourly for six hours and in total for 24 hours. Any and all adverse events related to furosemide were recorded including, but not limited to, tinnitus, hypokalemia, hypomagnesemia and hypotension. Patients were followed for 14 days or hospital discharge, whichever occurred first.

Outcomes

The primary outcome was the progression to AKIN stage III (need for RRT, increase in serum creatinine of 300% over baseline, urine output of 0.3 cc/kg/hour \times 24 hours) within 14 days of FST. The secondary outcome was the composite of achieving stage AKIN III or death within 14 days of the FST.

Statistics

We assessed the distribution of demographic and clinical variables. Differences between proportions of patients with certain characteristics were assessed with the chi-square, Fisher exact, Student *t*, and Mann-Whitney tests as appropriate. The primary analysis was to assess the urine output response to the FST, which was determined by assessing the area under the curve (AUC) receiver operating characteristics (ROC) comparing the primary endpoint of progression to AKIN stage III and the secondary endpoint of death/AKIN III within 14 days of the

FST. Multivariable logistic regression was used to create three models. Model 1 is a clinical model using the Acute Physiology and Chronic Health Evaluation (APACHE II) score, baseline urinary flow rate (UFR), baseline eGFR, and AKIN stage II at study entry. Model 2 has all univariate variables with a difference <0.10 entered as covariates. Model 3 is multivariate, backward elimination, logistic regression. All means are reported + standard error (SE) unless otherwise specified. Statistical analysis was performed using SPSS 18.0 (Chicago, Ill). Methodology used to calculate FeNa, APACHE II score[20], and cardiovascular (CV) SOFA[21] score and eGFR[22] is shown in Additional file 1.

Results and discussion

We assessed a total of 77 patients, 23 patients from cohort 1 and 54 from cohort 2 (Figure 1). The mean age was 65.3 ± 1.6 years; 42.8% were male: Among the patients 44 (57.1%) were African-American, 23 (29.9%) were Caucasian, and 10 (13%) were Hispanic (Table 1). Of the 77 patients, 25 (32.4%) met the primary outcome of AKIN Stage III and 16 (20.7%) died. Of the total cohort, 32 (41.5%) met the secondary composite endpoint of AKIN III or death within 14 days of the FST. Of the 25 patients who progressed to AKIN stage III, 11 (44.0%) received RRT.




Figure 1 Patient flow. eGFR, estimated glomerular filtration rate; FeNa, fractional excretion of sodium; AKIN, Acute Kidney Injury Network.

Table 1 Patient characteristics

Variable	Combined n = 77	Non-progressors n = 52	AKIN III n = 25	P
Age, years	65.3 (1.6)	63.8 (2.2)	68.2 (1.9)	0.13
Gender, % male	42.8%	36.5%	56.0%	0.14
Race, n (%)				
African American	44 (57.1%)	29 (55.6%)	15 (60.0%)	0.63
Caucasian	23 (29.9%)	15 (28.8%)	8 (32.0%)	0.92
Hispanic	10 (13.0%)	8 (15.4%)	2 (8.0%)	0.48
Comorbidities, n (%)				
CKD	24 (31.0%)	17 (32.7%)	7 (28.0%)	0.80
Hypertension	60 (78.0%)	41 (78.8%)	19 (76.0%)	0.78
CHF	25 (33.0%)	15 (29.0%)	10 (40.0%)	0.44
DM	35 (44.0%)	22 (41.5%)	13 (52.0%)	0.47
Nephrotoxic exposure, n (%)				
NSAIDs	8 (10.0%)	6 (2.0%)	2 (1.0%)	1.00
Aminoglycosides	1 (1.0%)	0 (0.0%)	1 (0.4%)	0.63
Amphotericin	2 (3.0%)	2 (4.0%)	0 (0.0%)	1.00
Contrast	21 (27.0%)	15 (28.8%)	6 (23.1%)	0.79
Post-cardiac surgery	9 (11.7%)	6 (11.5%)	3 (12.0%)	1.00
Sepsis	15 (19.5%)	12 (23.1%)	3 (12.0%)	0.36
Clinical Data				
Baseline eGFR, ml/minute/1.73m ²	68.6 (4.1)	60.0 (8.8)	73.3 (4.2)	0.15
Baseline UFR (ml/hr)	74.6 (11.6)	95.7 (16.3)	29.7 (4.2)	0.001
Furosemide-naïve, n (%)	29 (37.7%)	23 (44.2%)	6 (24.0%)	0.13
Urine cast score)	2.3 (0.13)	2.1 (0.16)	2.7 (0.23)	0.05
FeNa above 1%, n (%) ^a	14 (18.0%)	10 (19.2%)	4 (16.0%)	1.00
CV SOFA score	1.16 (0.3)	1.05 (0.2)	1.5 (0.4)	0.37
APACHE II score	17.8 (1.11)	16.5 (1.2)	21.6 (2.5)	0.08
AKIN stage at enrollment, n (%)				
AKIN I	41 (53.2%)	34 (65.4%)	7 (28.0%)	0.003
AKIN II	36 (46.7%)	18 (34.6%)	18 (72.0%)	0.003
Outcomes, n (%)				
Death	16 (20.7%)	7 (13.4%)	9 (36.0%)	0.04
AKIN stage III	25 (32.4%)	N/A	25 (100%)	N/A
RRT	11 (14.2%)	N/A	11 (44.0%)	N/A
Death/AKIN III	32 (41.5%)	7 (13.4%)	25 (100.0%)	0.001

Data are presented as mean ± standard error unless otherwise indicated. CKD, chronic kidney disease; CHF, congestive heart failure; DM, diabetes mellitus; NSAIDs, non-steroidal anti-inflammatory drugs; eGFR, estimated glomerular filtration rate; UFR, urinary flow rate; CV SOFA, Cardiovascular Sequential Organ Failure Assessment; APACHE, Acute Physiology and Chronic Health Evaluation; AKIN, Acute Kidney Injury Network; FeNa, fractional excretion of sodium; RRT, renal replacement therapy; RPP, renal perfusion pressure; n, number of patients; N/A, not applicable. ^aFeNa not assessed in 29 patients because the George Washington University Urine Sediment Score was already ≥2 at the time of assessment.

In the overall cohort, 24 patients (31%) had chronic kidney disease (CKD). The numbers of patients with diabetes mellitus (DM), hypertension (HTN), and congestive heart failure (CHF) were 35 (44%), 60 (78%), and 25 (33%), respectively. The proportion of patients with CKD, HTN, CHF, and DM was not statistically different between progressors and non-progressors (Table 1). There was no difference in the prevalence of sepsis or recent cardiac surgery in those who did and did not progress. Baseline serum albumin concentration was not different between progressors and non-progressors (2.82 g/dL versus

2.89 g/dL, $P = 0.89$). Baseline serum lactate concentrations were not different between those who did and did not progress (data not shown). The mean cardiovascular Sequential Organ Failure Assessment (SOFA) score was 1.16 (0.3) and the mean APACHE II score was 17.8 (1.11); there was no difference between progressors and non-progressors (Table 1).

The baseline UFR for the 6 hours before the FST was 74.2 (11.6) ml/hour. The baseline UFR was 95.7 (16.3) and 29.7 (4.2) in the non-progressor group and in the progressor group, respectively ($P < 0.01$). We assessed the capacity

of the UFR in absolute values (UFR-raw), the UFR corrected for ideal body weight (UFR-IBW), and the UFR corrected for actual body weight (UFR-ABW) to predict progression to AKIN stage III. The ROC AUC for UFR-raw, UFR-IBW, and UFR-ABW was 0.76 (0.09), 0.71 (0.08), and 0.76 (0.08), respectively (Additional file 1 - Table S2). Within the combined cohort of patients, 36 (46.8%) had AKIN stage II by either urine output (UO) or serum creatinine (Scr) criteria at time of enrollment. There were fewer patients with AKIN stage II amongst non-progressors ($n = 18$ (34.6%)) compared to progressors ($n = 18$ (72%)) ($P < 0.003$). In the combined cohort, the mean cast score was 2.3 (0.13). Non-progressors had a GW USS of 2.1 (0.16) compared to progressors who had a mean GW USS of 2.7 (0.23) ($P = 0.05$). The ROC AUC for GW USS to predict AKIN III was 0.63 (0.07). Patient characteristics of progressors and non-progressors are shown in Table 1. Patient characteristics in cohorts 1 and 2 are shown in Additional file 1 - Table S3.

FST urine output (for each increase of 10 ml of UO) was predictive of non-progression to AKIN stage III when baseline patient imbalances were placed into a multivariate logistic regression analysis (odds ratio (OR) 0.98, 95% CI 0.96, 0.99, $P = 0.05$). Multivariable logistic analyses are shown in Additional file 1 - Table S4.

Furosemide stress test characteristics

The FST was well-tolerated with no episodes of hypotension or any other adverse event deemed attributable to the test. We assessed the UFR in response to furosemide. The maximum UFR was within the first 2 to 3 hours (Table 2, Figure 2). We compared the UFR in response to FST between those patients that progressed and did not progress to AKIN stage III (Table 2, Figure 2). For each hourly interval, progressors had a lower UFR response compared to non-progressors ($P < 0.001$). We also compared the UFR of FST between subjects who were furosemide naïve versus those that were not; there was no difference between these (Additional file 1 - Table S5).

We tested various combinations of the UO intervals to assess which had the best discriminative capacity (Table 3). We found that the sum of the first 2 hours of UO after the

FST had the highest AUC to predict the primary outcome (0.87 in both cohort 1 and cohort 2). We also assessed the sensitivity and specificity of various 2-hour urine volumes to predict the primary and secondary outcomes (Table 4). The 2-hour UO of 200 ml or less had the best sensitivity and specificity to predict the primary outcome.


In this pilot study, we have demonstrated that the FST is feasible and well tolerated in critically ill patients with AKI. Furosemide administration can be associated with vasodilation and hypotension, but we did not observe any of these complications during our study. We took careful measures to decrease this potential adverse event by ensuring that the patients were deemed clinically well-resuscitated, and when appropriate received isovolemic replacement of UO with isotonic fluids. This may in part explain why we did not observe any adverse events.

The performance of the FST to predict the primary outcome was robust and consistent in both cohorts, with a range in ROC AUC of 0.82 to 0.87 (Table 3). Importantly, in comparison, the capacity of baseline UFR to predict the primary outcome had an ROC AUC of 0.71 to 0.76 (Additional file 1 - Table S2). This finding supports the concept that the FST offers important clinical information not captured by baseline UFR alone. In our study, the performance of the FST was comparable or exceeded the performance of several AKI biomarkers in predicting AKI progression [6,8,9]. We found the first 2-hour interval had the best predictive capacity (0.87), and this interval corresponds with the maximum UFR in response to the FST. When we assessed specific UO cutoffs we found that the 2-hour UO of 200 cc offered the best combination of sensitivity and specificity (87.1% and 84.1%, respectively). Because acute tubular necrosis causes intratubular obstruction and back leak, we were unsure whether the standard UO kinetics in response to furosemide would be similar to those seen in patients without renal disease [23,24]. Previous investigators have shown that in patients without AKI, the maximum diuretic effect of furosemide occurs within the first three hours [25]. We showed similar kinetics in our study (Figure 2). Patients who progressed to AKIN III compared to those that did not progress were similar in age, CV SOFA score, APACHE II score, and baseline eGFR, and

Table 2 Furosemide stress test effect on urine flow

Measurement time point	Combined $n = 77$	Non-progressors $n = 52$	Progressed to AKIN III $n = 25$	p
Hour 1	251 (35.2)	329 (46.0)	89 (33.0)	0.001
Hour 2	296 (35.8)	392 (42.2)	96 (46.6)	0.001
Hour 3	246 (26.6)	311 (31.7)	109 (35.4)	0.001
Hour 4	207 (24.1)	265 (31.1)	88 (23.4)	0.001
Hour 5	175 (18.6)	219 (22.8)	83 (23.7)	0.001
Hour 6	155 (17.4)	194 (22.3)	75 (17.4)	0.001

Urine volume in ml is shown as mean (standard error). AKIN, Acute Kidney Injury Network; n, number of patients.



had a similar incidence of comorbidity (Table 1). Nephrotoxic exposure and clinical phenotype was also similar in progressors and non-progressors (Table 1). Not surprisingly, the progressor group tended to have more patients with AKIN stage II, a lower baseline UFR, and a higher mean cast score prior to FST. In multivariable analyses, UO response to FST was still statistically associated with progression to AKIN stage III, even when these variables were placed into the model (Additional file 1 - Table S4).

The concept of using furosemide to evaluate AKI is not entirely new. In 1973, Baek and colleagues [26] assessed 15 patients who did not have clinically apparent AKI at that time, subjected them to a furosemide challenge, and then evaluated the patients' free water clearance (C_{H_2O}). They found that C_{H_2O} near zero and a poor response to furosemide signaled that 'acute renal failure was imminent'. In this modest sized study, the dose of furosemide was not standardized and the study did not report if the patients had early stage AKI or any evidence of AKI at all. Nonetheless, our findings confirm the findings of that original report. Moreover, clinicians regularly give patients with oliguric AKI a furosemide challenge. However, there

has not been a standardized approach with fluid replacement, early assessment, and appropriate clinical cutoffs to guide care.

In this study, we have used the FST as a functional test to predict progressive AKI. Urine biomarkers have been used previously to predict worsening AKI. The predictive value of the FST compares favorably with other recent biomarker studies. Hall and colleagues determined the ability of urine neutrophil gelatinase associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1) and IL-18 to predict worsening AKI (unadjusted AUC values were 0.71, 0.64 and 0.63 respectively) [27]. The TRIBE-AKI consortium found unadjusted AUC values of 0.63 for IL-18, and 0.58 and 0.74 for urinary and plasma NGAL, respectively [6]. Koyner and colleagues in a separate study found that π -glutathione S-transferase (GST) predicted progression to stage III AKI with an AUC of 0.86 [28]. We recently found that urinary angiotensinogen predicts worsening AKI with an AUC of 0.70 [17].

Although the findings in this study show good performance metrics for the FST, the use of the FST in patients who are not appropriately resuscitated can be potentially

Table 3 Furosemide stress test receiver operation characteristics for progression to AKIN Stage III

A			
Urine output measurement time point	ROC AUCs		
	Cohort 1 n = 23	Cohort 2 n = 54	Combined n = 77
One hour	0.83 (0.11)	0.82 (0.07)	0.82 (0.05)
Two hours	0.87 (0.09)	0.87 (0.07)	0.87 (0.05)
Three hours	0.84 (0.09)	0.87 (0.07)	0.86 (0.05)
Four hours	0.85 (0.09)	0.87 (0.07)	0.86 (0.05)
Five hours	0.85 (0.09)	0.87 (0.07)	0.85 (0.05)
Six hours	0.85 (0.09)	0.86 (0.07)	0.85 (0.05)

B Furosemide stress test receiver operation characteristics for progression to AKIN stage III or death

B			
Urine output measurement time point	ROC AUCs		
	Cohort 1 n = 23	Cohort 2 n = 54	Combined n = 77
One hour	0.86 (0.11)	0.74 (0.08)	0.79 (0.06)
Two hours	0.89 (0.09)	0.76 (0.08)	0.81 (0.06)
Three hours	0.87 (0.09)	0.76 (0.08)	0.80 (0.06)
Four hours	0.87 (0.09)	0.76 (0.08)	0.80 (0.06)
Five hours	0.88 (0.09)	0.77 (0.08)	0.81 (0.06)
Six hours	0.87 (0.09)	0.76 (0.08)	0.80 (0.06)

The outcome was Acute Kidney Injury Network (AKIN) stage III only within 14 days of the FST. One hour is the first hour after the furosemide stress test (FST), two hours is the sum of the first and second hour after the FST. All measurements shown were significant at $P < 0.01$. ROC AUC, receiver operating characteristic area under the curve.

Primary outcome was Acute Kidney Injury Network (AKIN) stage III or death within 14 days of furosemide stress test (FST). One hour is the first hour after the FST, two hours is the sum of the first and second hour after the FST. All measurements shown were significant at $P < 0.01$. ROC AUC, receiver operating characteristic area under the curve; n, number of patients.

deleterious. We cannot overemphasize the point that patients need to be euvolemic before undertaking any type of furosemide challenge, and that volume replacement is mandatory in patients who are not obviously volume overloaded, as the mean UO in response to the challenge was

over 1.3 L in 6 hours. In addition, the FST should be conducted in an appropriate clinical setting where UO, heart rate, and blood pressure can be monitored frequently.

The study has several limitations. Since this is a pilot study, larger more comprehensive studies of the FST are

Table 4 Sensitivity and specificity of two hour urine thresholds for progression to AKIN stage III

A		
Total urine output over 2 hours	Combined cohort	
	Sensitivity	Specificity
≤100 ml	90.2%	60.0%
<200 ml	87.1%	84.1%
<300 ml	85.3%	88.0%
<400 ml	66.7%	88.0%
<500 ml	50.5%	88.0%

B Sensitivity and specificity of two hour urine thresholds for progression to AKIN III or death

B		
Total urine output over two hours	Combined cohort	
	Sensitivity	Specificity
<100 ml	93.3%	53.2%
<200 ml	90%	74.2%
<300 ml	87.8%	77.4%
<400 ml	66.7%	77.4%
<500 ml	53.3%	77.4%

The primary outcome was Acute Kidney Injury Network (AKIN) stage III within 14 days of the furosemide stress test.

The primary outcome was Acute Kidney Injury Network (AKIN) stage III or death within 14 days of the furosemide stress test.

warranted in order to fully understand the advantages and disadvantages of this dynamic functional test. Although previous clinical trials of furosemide use in AKI have **not shown any beneficial effect**, we cannot be sure that the FST did not impact the natural history of AKI and therefore affect its predictive performance [29,30]. **Some** investigators have suggested that furosemide is **protective** in AKI because its administration **may decrease tubular oxygen consumption**, in which case its early administration in AKI would be protective [31]. Clinical **trials** using furosemide **early** in the course of AKI are **underway** and may help determine whether **furosemide** has a **role** in the **treatment** of AKI [32]. In addition, we did not specifically study patients with acute decompensated heart failure, nephrotic syndrome, or other patient populations with diuretic resistance. As such, we cannot be certain that the FST will perform similarly in those patient populations.

Similar to the approach used in **acute coronary syndrome** **before** the advances in **thrombolytic** therapy, the clinical syndrome of angina (that is, chest pain and dyspnea) was followed by a biomarker assessment (that is, creatine phosphokinase-MB) to further risk-assess the patient. For those patients who were confirmed with a biomarker, **stress testing** (for example, dobutamine or treadmill stress test) was used to **confirm** the **presence** of severe coronary artery disease. We believe that a **similar process** can begin in patients with AKI. Patients with renal angina [33] can be further assessed with AKI biomarkers. For those patients in whom AKI biomarkers confirm AKI, **FST could be used to assess the severity and prognosis of AKI**. Because indiscriminate use of loop diuretics can be harmful, appropriate resuscitation prior to FST is mandatory, and the FST should not be used as a primary screening diagnostic. We suggest that future studies to test this hypothesis be conducted.

Conclusions

In summary, the FST is a novel dynamic functional assessment of tubular function that has good predictive capacity to identify those patients who will progress to advanced-stage AKI. Combinations of risk assessment, AKI biomarkers, and response to the **FST may be used to help answer the important clinical question: 'When, or, should I start RRT in my patient with AKI?'**

Key Messages

- The furosemide stress test (FST) is feasible and well-tolerated in critically ill patients with early AKI.
- The performance of the **FST** to **predict** the primary outcome was robust and consistent in both cohorts, with a range in ROC AUC of 0.82 to 0.87.
- Patients should be **euvolemic** **before** undertaking any type of furosemide challenge, and **volume replacement**

is mandatory in patients who are not obviously volume overloaded.

- FST should be conducted in an appropriate clinical setting where UO, heart rate, and blood pressure can be monitored frequently.
- FST is a novel dynamic functional assessment of tubular function that appears to have **good predictive capacity to identify those patients who will progress to advanced-stage AKI**. Further validation studies of the FST are warranted.

Additional material

Additional file 1: Supplementary Methods, Table S1 to S5.

Abbreviations

ABW: actual body weight; AKIN: Acute Kidney Injury Network; AKI: acute kidney injury; APACHE: Acute Physiology and Chronic Health Evaluation; AUC: area under the curve; CHF: congestive heart failure; CKD: chronic kidney disease; CV: cardiovascular; DM: diabetes mellitus; eGFR: estimated glomerular filtration rate; FeNa: fractional excretion of sodium; FST: furosemide stress test; GW USS: George Washington University Urine Sediment Score; hOAT: human organic acid transporter; HTN: hypertension; IL-18: interleukin 18; IBW: ideal body weight; KIM-1: kidney injury molecule -1; NGAL: neutrophil gelatinase associated lipocalin; OR: odds ratio; π -GST: π -glutathione S-transferase; RRT: renal replacement therapy; ROC: receiver operating characteristic; SAKInet: Southern Acute Kidney Injury Network; Scr: serum creatinine; SOFA: Sequential Organ Failure Assessment; UFR: urinary flow rate; UO: urine output.

Competing interests

LSC has links with Abbott Medical, Astute Medical, Alere Medical, Gambro Medical and Nxstage Medical. DLD has links with Astute Medical. JLK has links with Astute Medical, Abbott Medical, and Argutus Medical. ADS has links with Astute Medical. JAT has links with Astute Medical. All other authors declare that they have no competing interests.

Authors' contributions

All authors read and approved the final manuscript. LSC conceived the study, helped conduct the trial and the literature search, made the Figures, collected data, performed data analysis and interpretation, and wrote the manuscript. DLD helped conduct the trial, collect data, perform the literature search, data analysis and interpretation, and wrote the manuscript. EBM helped conduct the trial, collect data, perform data analysis and interpretation, and wrote the manuscript. JLK helped conduct the trial, collected data, data analysis, interpretation, and wrote the manuscript. JMA did data analysis, literature search, interpretation, and wrote the manuscript. ADS did data analysis, interpretation, and wrote the manuscript. JAT did data analysis, interpretation, and wrote the manuscript. SAT helped conduct the trial, collected data, and performed data analysis. PLK did the literature search, data analysis and interpretation, and wrote the manuscript. MGS did data analysis and interpretation, and wrote the manuscript.

Acknowledgements

The SAKInet portion of this study was funded by National Institutes of Health, NIDDK, NIH grant number R01 DK080234. JLK was supported by K23DK081616. The investigators would like to thank all of the nurses and support staff of the George Washington University Hospital Jack Zimmerman Intensive Care Unit for their assistance in all of our clinical research. The investigators would also like to acknowledge Christina Seneff and Lindita Shelu for their assistance in conducting this study. The authors would like to thank Oscar Medales, Dan Barker, Welshi Ladde, Astra Fudgeri, and Gary R Snyder for reviewing the manuscript and offering suggestions. LSC and JAT would like to thank Robert Safirstein for his input into the development of this protocol.

Authors' details

¹Department of Anesthesiology and Critical Care Medicine, George Washington University Medical Center, 900 23rd street, Washington DC, 20037, USA. ²Division of Renal Diseases and Hypertension, Department of Medicine, George Washington University Medical Center, 2150 Pennsylvania Avenue, Washington DC, 20037, USA. ³Section of Nephrology, Department of Medicine, University of Chicago, 5841 South Maryland Avenue, Chicago, IL, 60637, USA. ⁴829 CSB Division of Nephrology, Department of Medicine, Medical University of South Carolina, 96 Jonathan Lucas, Charleston, SC, 250623, USA. ⁵Department of Anesthesiology, Duke University/Durham VAMC, Durham, DUMC 3094, Durham, NC, 27710, USA. ⁶Renal Division, University of Tennessee College of Medicine at Chattanooga, 251 North Lysterly Street, Chattanooga, TN, 37404, USA. ⁷Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes, Digestive, and Kidney Diseases, NIH, 6707 Democracy Blvd, Bethesda, MD, 20817, USA.

Received: 27 February 2013 Revised: 28 April 2013

Accepted: 20 September 2013 Published: 20 September 2013

References

- Bellomo R, Kellum JA, Ronco C: **Acute kidney injury.** *Lancet* 2012, **380**:756-766.
- Coca SG, Singanamala S, Parikh CR: **Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis.** *Kidney Int* 2012, **81**:442-448.
- Hsu RK, McCulloch CE, Dudley RA, Lo LJ, Hsu CY: **Temporal changes in incidence of dialysis-requiring AKI.** *J Am Soc Nephrol* 2013, **24**:37-42.
- Gibney N, Hoste E, Burdmann EA, Bunchman T, Kher V, Viswanathan R, Mehta RL, Ronco C: **Timing of initiation and discontinuation of renal replacement therapy in AKI: unanswered key questions.** *Clin J Am Soc Nephrol* 2008, **3**:876-880.
- Seabra VF, Balk EM, Liangos O, Sosa MA, Cendoroglo M, Jaber BL: **Timing of renal replacement therapy initiation in acute renal failure: a meta-analysis.** *Am J Kidney Dis* 2008, **52**:272-284.
- Koynner JL, Garg AX, Coca SG, Sint K, Thiessen-Philbrook H, Patel UD, Shlipak MG, Parikh CR: **Biomarkers predict progression of acute kidney injury after cardiac surgery.** *J Am Soc Nephrol* 2012, **23**:905-914.
- Chawla LS, Kellum JA: **Acute kidney injury in 2011: Biomarkers are transforming our understanding of AKI.** *Nat Rev Nephrol* 2012, **8**:68-70.
- Bonventre JV: **Diagnosis of acute kidney injury: from classic parameters to new biomarkers.** *Contrib Nephrol* 2007, **156**:213-219.
- Devarajan P: **Emerging biomarkers of acute kidney injury.** *Contrib Nephrol* 2007, **156**:203-212.
- Doi K, Noiri E, Sugaya T: **Urinary L-type fatty acid-binding protein as a new renal biomarker in critical care.** *Curr Opin Crit Care* 2010, **16**:545-549.
- Hasannejad H, Takeda M, Taki K, Shin HJ, Babu E, Jutabha P, Khamdang S, Aleboyeh M, Onozato ML, Tojo A, Enomoto A, Anzai N, Narikawa S, Huang XL, Niwa T, Endou H: **Interactions of human organic anion transporters with diuretics.** *J Pharmacol Exp Ther* 2004, **308**:1021-1029.
- Bowman RH: **Renal secretion of [35-S]furosemide and depression by albumin binding.** *Am J Physiol* 1975, **229**:93-98.
- Burg M, Stoner L, Cardinal J, Green N: **Furosemide effect on isolated perfused tubules.** *Am J Physiol* 1973, **225**:119-124.
- Dirks JH, Seely JF: **Effect of saline infusions and furosemide on the dog distal nephron.** *Am J Physiol* 1970, **219**:114-121.
- Brater DC, Anderson SA, Strowig S: **Azosemide, a "loop" diuretic, and furosemide.** *Clin Pharmacol Ther* 1979, **25**:435-439.
- Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A: **Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury.** *Crit Care* 2007, **11**:R31.
- Alge JL, Karakala N, Neely BA, Janech MG, Tumlin JA, Chawla LS, Shaw AD, Arthur JM: **Urinary Angiotensinogen and Risk of Severe AKI.** *Clin J Am Soc Nephrol* 2013, **8**:184-193.
- Chawla LS, Domm A, Berger A, Shih S, Patel SS: **Urinary sediment cast scoring index for acute kidney injury: a pilot study.** *Nephron Clin Pract* 2008, **110**:c145-150.
- Loon NR, Wilcox CS, Unwin RJ: **Mechanism of impaired natriuretic response to furosemide during prolonged therapy.** *Kidney Int* 1989, **36**:682-689.
- Knaus WA, Zimmerman JE, Wagner DP, Draper EA, Lawrence DE: **APACHE-acute physiology and chronic health evaluation: a physiologically based classification system.** *Crit Care Med* 1981, **9**:591-597.
- Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG: **The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine.** *Intensive Care Med* 1996, **22**:707-710.
- Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: **A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.** *Ann Intern Med* 1999, **130**:461-470.
- Arendshorst WJ, Finn WF, Gottschalk CW: **Pathogenesis of acute renal failure following temporary renal ischemia in the rat.** *Circ Res* 1975, **37**:558-568.
- Bird JE, Milhoan K, Wilson CB, Young SG, Mundy CA, Parthasarathy S, Blantz RC: **Ischemic acute renal failure and antioxidant therapy in the rat. The relation between glomerular and tubular dysfunction.** *J Clin Invest* 1988, **81**:1630-1638.
- Chennavasin P, Seiwell R, Brater DC, Liang WM: **Pharmacodynamic analysis of the furosemide-probenecid interaction in man.** *Kidney Int* 1979, **16**:187-195.
- Baek SM, Brown RS, Shoemaker WC: **Early prediction of acute renal failure and recovery. I. Sequential measurements of free water clearance.** *Ann Surg* 1973, **177**:253-258.
- Hall IE, Coca SG, Perazella MA, Eko UU, Luciano RL, Peter PR, Han WK, Parikh CR: **Risk of poor outcomes with novel and traditional biomarkers at clinical AKI diagnosis.** *Clin J Am Soc Nephrol* 2011, **6**:2740-2749.
- Koynner JL, Vaidya VS, Bennett MR, Ma Q, Worcester E, Akhter SA, Raman J, Jeevanandam V, O'Connor MF, Devarajan P, Bonventre JV, Murray PT: **Urinary biomarkers in the clinical prognosis and early detection of acute kidney injury.** *Clin J Am Soc Nephrol* 2010, **5**:2154-2165.
- Mehta RL, Pascual MT, Soroko S, Chertow GM: **Diuretics, mortality, and nonrecovery of renal function in acute renal failure.** *Jama* 2002, **288**:2547-2553.
- Ho KM, Power BM: **Benefits and risks of furosemide in acute kidney injury.** *Anaesthesia* 2010, **65**:283-293.
- Heyman SN, Rosen S, Epstein FH, Spokes K, Brezis ML: **Loop diuretics reduce hypoxic damage to proximal tubules of the isolated perfused rat kidney.** *Kidney Int* 1994, **45**:981-985.
- Bagshaw SM, Gibney RT, McAlister FA, Bellomo R: **The SPARK Study: a phase II randomized blinded controlled trial of the effect of furosemide in critically ill patients with early acute kidney injury.** *Trials* 2010, **11**:50.
- Goldstein SL, Chawla LS: **Renal angina.** *Clin J Am Soc Nephrol* 2010, **5**:943-949.

doi:10.1186/cc13015

Cite this article as: Chawla et al.: Development and Standardization of a Furosemide Stress Test to Predict the Severity of Acute Kidney Injury. *Critical Care* 2013 **17**:R207.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

